TradingView report covering Cytosorbents Corporation (CTSO) market action, institutional positioning, and fundamental catalysts.
Why CTSO Stock surged +3.18% Today — RQD Quant Desk Flash
Cytosorbents Corporation (CTSO) carries a Roarable Rating of E (Strong Sell) with 22/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is CTSO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Cytosorbents Corporation (NASDAQ: CTSO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 22/100 at a spot price of $4.54 (+3.18% 1D, market cap $14.3M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 6/20, FRED Macro Regime Fit 4/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CTSO ranks #965 in composite RQD confidence.
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does CTSO compare to PAVM and GUTS in the Health Care sector?
▼
Within the Health Care sector (Medical/Dental Instruments), CTSO carries a Roarable E (22/100 RQD), trailing P/E of N/A, gross margin of 71.5%, and ROIC of -35.0%. By comparison, PAVM (PAVmed Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $15.6M) and GUTS (Fractyl Health Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $13.0M). Among the 5-stock peer group, CTSO leads on earnings multiple (N/A) while CTSO leads on capital efficiency (-35.0% ROIC).
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for CTSO?
▼
Per CTSO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001175151), Cytosorbents Corporation generated $37.1M in revenue (+4.1% YoY), -$8.2M in net income, and -$12.5M in free cash flow against $44.2M in total assets and $16.7M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
20D Institutional Volume Accumulation (±12.5% realized swing band)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
⚔️ Adversarial Opposing Case: What Could Spark a CTSO Turnaround Squeeze
While CTSO currently carries a cautious 22/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.18) and Max Pain ($4.77) forces dealer call-delta covering toward $17.85.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Why CTSO Stock surged +3.18% Today — RQD Quant Desk Flash
Cytosorbents Corporation (CTSO) surged +3.18% to $4.54, trading at 12% of its 52-week range ($2.84 – $17). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 12% of its 52-week range ($2.84 – $17) with RSI-14 at 48.1 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $4.54 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 71.5% gross margin and $0 annual free cash flow.
Yahoo Finance UK report covering Cytosorbents Corporation (CTSO) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Cytosorbents Corporation (CTSO) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Cytosorbents Corporation (CTSO) market action, institutional positioning, and fundamental catalysts.
Kalkine report covering Cytosorbents Corporation (CTSO) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Cytosorbents Corporation (CTSO) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Cytosorbents Corporation (CTSO) market action, institutional positioning, and fundamental catalysts.
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report third quarter 2026 financial results
Gainers Pomdoctor (NASDAQ:POM) shares rose 25.6% to $1.47 during Friday's after-market session. The market value of their outstanding shares is at $8.3 million. GeneDx Holdings (NASDAQ:WGS) shares rose 8.72% to
WBB Securities analyst Karen Sterling initiates coverage on CytoSorbents (NASDAQ:CTSO) with a Speculative Buy rating and announces Price Target of $9.5.
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CTSO)
- ✓Walkthrough of CTSO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
CTSO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CTSO today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CTSO. Explore sector supply chains on /butterfly.
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CTSO)
1. Head-to-Head Health Care Peer Comparison (CTSO vs. PAVM, GUTS, CNSY, SINT)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Cytosorbents Corporation (CTSO) ranks #965 by composite RQD confidence (22/100, grade E) and #859 by equity capitalization ($14.3M). Within this direct 5-issuer industry benchmark cohort, CTSO leads on earnings valuation at N/A trailing P/E, while CTSO leads on capital efficiency and profitability with -35.0% ROIC and 71.5% gross margin. GUTS currently holds the highest overall quantitative score in the immediate peer group at 34/100 (E) compared with CTSO at 22/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CTSO
ACTIVE
Cytosorbents Corporation | E | 22/100 | — | 71.5% | -35.0% | +3.18% | $14.3M | Benchmark Subject |
| PAVM PAVmed Inc. | E | 28/100 | — | -30.0% | -35.0% | -1.01% | $15.6M | /pavm-vs-ctso → |
| GUTS Fractyl Health Inc. | E | 34/100 | — | — | -35.0% | -1.51% | $13.0M | /guts-vs-ctso → |
| CNSY Cerenome Inc. | E | 25/100 | — | — | -35.0% | -2.30% | $12.9M | /cnsy-vs-ctso → |
| SINT SiNtx Technologies Inc. | E | 33/100 | — | 45.3% | -35.0% | -1.16% | $12.8M | /sint-vs-ctso → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001175151In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cytosorbents Corporation (CTSO) reported GAAP revenue of $37.1M (+4.1% vs. FY2024 revenue of $35.6M ) , GAAP net income of -$8.2M, operating cash flow of -$12.4M, and free cash flow of -$12.5M (+14.8% YoY). On the balance sheet, CTSO closed FY2025 with $44.2M in total assets against $16.7M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $37.1M | -$8.2M | -$12.4M | -$12.5M | $44.2M | $16.7M |
| FY2024 (FY) | 2024-12-31 | $35.6M | -$20.7M | -$14.4M | -$14.7M | $47.4M | $14.0M |
| FY2023 (FY) | 2023-12-31 | $0 | -$29.2M | -$21.7M | -$21.7M | — | — |
3. CTSO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs CTSO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Cytosorbents Corporation (NASDAQ: CTSO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 22/100 at a spot price of $4.54 (+3.18% 1D, market cap $14.3M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 6/20, FRED Macro Regime Fit 4/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CTSO ranks #965 in composite RQD confidence.
How does CTSO compare to PAVM and GUTS in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), CTSO carries a Roarable E (22/100 RQD), trailing P/E of N/A, gross margin of 71.5%, and ROIC of -35.0%. By comparison, PAVM (PAVmed Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $15.6M) and GUTS (Fractyl Health Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $13.0M). Among the 5-stock peer group, CTSO leads on earnings multiple (N/A) while CTSO leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for CTSO?
Per CTSO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001175151), Cytosorbents Corporation generated $37.1M in revenue (+4.1% YoY), -$8.2M in net income, and -$12.5M in free cash flow against $44.2M in total assets and $16.7M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is CTSO trading relative to its 50-day, 200-day, and 52-week technical levels?
CTSO last traded at $4.54 (+3.18% on volume of 24,121 shares), positioning the stock -12.36% below its 50-day simple moving average ($5.18) and -51.70% below its 200-day simple moving average ($9.40). Across its 52-week range of $2.84 to $17.00, CTSO sits at the 12.0% percentile with a 14-day RSI of 48.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.97 to $5.11).
CTSO Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is CTSO stock moving today?
Why CTSO Stock surged +3.18% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
CTSO — Cytosorbents Corporation: What the Facts Mean to a Prospective Investor
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, CTSO scores 22 out of 100, a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars: the Fundamental Cash Engine scores 4/20 (ROIC -35%; FCF yield 0%); Whale 13F Flow scores 5/20 (institutional accumulation and options positioning); Insider Conviction scores 3/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit scores 4/20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet scores 6/20 (Altman Z 2.5; Piotroski F 3/9; Debt/Equity 2.82).
For a prospective investor, the pillar profile points to weak cash generation as the central issue: a negative ROIC and a 0% FCF yield mean the business is not currently converting capital into free cash for shareholders. The forensic pillar reflects a leveraged balance sheet (Debt/Equity 2.82) and a Piotroski F-Score of 3 out of 9, which signals limited financial-quality strength. The Insider and 13F pillars are also low, indicating weak conviction signals in the available flow data. The main upside driver implied by the data is any sustained improvement in operating income, since the reported operating margin of -39.8% leaves substantial room for margin repair; however, the source data does not establish that such improvement is underway. Valuation tradeoffs are difficult to assess because P/E, Forward P/E, and EV/EBITDA are not available in source data. The market capitalization of $13.9M against FY 2025 debt of $16.7M illustrates how thin the equity cushion appears relative to liabilities. The 52-week range of $2.84 - $17 reflects extreme price volatility, which is consistent with the rating's forensic-risk label.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $37.1M | $-14.7M | $-8.2M | N/A | $-12.5M | $6.2M | $16.7M |
| FY 2024 | $35.6M | $-16.5M | $-20.7M | N/A | $-14.7M | $3.3M | $14.0M |
| FY 2023 | $0.0M | $-31.9M | $-29.2M | N/A | $-21.7M | N/A | N/A |
Per the SEC financials, net losses narrowed from $-29.2M in FY 2023 to $-8.2M in FY 2025, while revenue rose from $0.0M to $37.1M across the same span. Gross margin is reported at 71.5%, but operating margin is -39.8% and net margin is -22.1%, with ROIC at -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 3 out of 9, with Debt/Equity at 2.82. These forensic readings indicate a balance sheet under meaningful strain with weak financial-quality signals.
Recent Catalysts & News Wire Analysis
Per the recent news and catalysts feed, the headlines include a TradingView estimates report, a Yahoo Finance UK seasonal returns chart, an Investing.com note that WBB Securities initiated coverage with a Speculative Buy rating, a Stock Titan item noting a live Q&A following third-quarter results on Nov. 12, a Kalkine report on scheduling Q3 2026 results, and a TradingView item stating a Q3'26 revenue estimate of 9.90M USD. All items are tagged with a YELLOW light and MARKET WIRE impact label. Key catalyst watch items are the Q3 2026 results and live Q&A on Nov. 12 and the revenue estimate of 9.90M USD. Per the Butterfly Supply-Chain Graph, there are no supply-chain links and no proprietary signals recorded.
Open Questions
- What are the company's specific products, customers, and revenue drivers, given that the source data only provides sector classification?
- What are the trailing and forward earnings and valuation multiples, which are absent from the source data?
- What is the composition of the FY 2025 debt of $16.7M, including maturity schedule and covenant terms?
- What drove the revenue increase from $35.6M in FY 2024 to $37.1M in FY 2025, and what is the trajectory of operating losses?
- Who holds the shares, and is there any analyst coverage or insider activity beyond the single WBB Securities initiation headline?
CTSO Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Cytosorbents Corporation (CTSO) • Click "Debate This Headline" to argue it in the Roar Pit below
TradingView report covering Cytosorbents Corporation (CTSO) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering Cytosorbents Corporation (CTSO) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Cytosorbents Corporation (CTSO) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Cytosorbents Corporation (CTSO) market action, institutional positioning, and fundamental catalysts.
Kalkine report covering Cytosorbents Corporation (CTSO) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Cytosorbents Corporation (CTSO) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Cytosorbents Corporation (CTSO) market action, institutional positioning, and fundamental catalysts.
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report third quarter 2026 financial results
CTSO Bull vs. Bear Conversation Board — What's Your Call at $4.54?
🔥 Official Bull vs. Bear Debate: Is CTSO (E • RQD 22/100) a Buy at $4.40?
Welcome to the CTSO (Cytosorbents Corporation) Roar Pit. Current RQD Composite is 22/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Pump the brakes on CTSO — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on CTSO, but look at what you are paying: current EV/EBITDA multiples with 71.5% gross margins. Unless Cytosorbents Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
CTSO cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on CTSO, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $4.40 (52-wk range $2.84 - $17.00), any beat on forward guidance forces shorts and underweight funds to chase.